BridgeBio taps VCs for $200M, fueling oncology spinout's push to surpass KRAS class

BridgeBio taps VCs for $200M, fueling oncology spinout's push to surpass KRAS class

Source: 
Fierce Biotech
snippet: 

BridgeBio Pharma has spun its Rolodex to fund a subset of its sprawling list of opportunities. Busy with launch and late-phase activities, BridgeBio has secured $200 million to equip a cancer-focused offshoot to push a pipeline led by a KRAS inhibitor through early-phase tests.